An Epigenetic Change Causes the Block of Antitumor Genes
News Jun 12, 2013
This balance is disrupted in tumor cells. There are many causes, for example, the existence of mutations, but also the acquisition of a chemical signal, methylation, which blocks the activity of genes that stop cancer growing. It is unknown, however, what happens in the cells after they have acquired this epigenetic alteration.
Researchers of the IDIBELL, led by Manel Esteller, director of the Epigenetics and Cancer Biology Program, ICREA researcher and professor at the University of Barcelona, describe in the online edition of the journal Oncogene how this methylation triggers a dimensional change in the nucleus cell to form spherical structures called nucleosomes that block the function of antitumor genes.
Researchers observed that genes that protect from cancer as the vitamin A receptor alter its activity in colon cancer cells by the presence of spherical structures formed by DNA (in this case expression regulatory regions of genes) and proteins called histones.
"We have observed," said the researcher Manel Esteller, "that epigenetic drugs, capable of demethylating DNA, approved for patients with a subtype of leukemia, are also able to eliminate these 'balls' of antitumor genes so that they can express again, and recover their function."
“This study”, explained Esteller, “also served to discover new genes, inhibitors of cancer.”
The discovery increases the molecular understanding of the causes of cancer and as to the clinical application of the discovery; Esteller explained that "there is currently a wide range of drugs in preclinical development capable of ejecting nucleosomes of aberrant places of the genome".
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018